This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Thank you for standing by and welcome to the Q2 2022 Vanda Pharmaceuticals, Inc. earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, again, press the star one. Thank you. I'd now like to turn the conference over to Kevin Moran. Vanda's Senior Vice President, Chief Financial Officer, and Treasurer. Mr. Moran, please go ahead.
spk04: Thank you very much, Jack. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' second quarter 2022 performance. Our second quarter 2022 results were released this afternoon and are available on the SEC's Edgar system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mahalis Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board. Additionally, we have Tim Williams, our General Counsel, and Gunther Biersnix, our Senior Vice President of Business Development and R&D Committee Member. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances, and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors, and management's discussion and analysis of financial condition and results of operations sections of our annual report on Form 10-K for the fiscal year ended December 31, 2021, as updated by our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K, and other filings with the SEC. which are available on the SEC's EDGAR system and on our website. We encourage all investors to read these reports and our other filings. The information we provide on this call is provided only as of today, and we undertake no obligation to update or revise publicly any forward-looking statements we may make on this call on account of new information, future events, or otherwise, except as required by law. With that said, I would now like to turn the call over to our CEO, Dr. Mahalis Polymeropoulos.
spk06: Thank you very much, Kevin, and good afternoon, everyone. Thank you for joining us to discuss the second quarter 2022 results. We will proceed with Kevin discussing operational highlights and financial results for the quarter. Following that, we will open the line for questions, and I will now turn the call back to Kevin.
spk03: Thank you very much, Miles.
spk04: I'm excited to discuss the progress we've made on commercial and clinical development initiatives over the past several months and to provide updates on upcoming milestones that we believe will deliver significant momentum for the business leading into 2023. Looking first at commercial performance, we continue to advance our strategy and remain committed to strong financial execution. For several quarters, we have discussed payer challenges for Hetlius, with denials for sighted patients with non-24 remaining an issue. We are focused on progressing efforts with Medicare and Medicaid, and we have outlined successes with state Medicaid programs specifically in previous quarters. To date, more than 15 states have revised or agreed to revise their Medicaid prior authorization criteria to broaden access to Hetlios for patients with non-24 and nighttime sleep disturbances in Smith-McGinnis syndrome, which is encouraging. On the Medicare side, we are seeing some progress as well. In July 2022, a sighted non-24 patient secured a key victory in a coverage dispute with a Medicare Part B plan, which had a coverage policy restricting hetlios coverage for non-24 on the basis of vision status. Following an appeal, an administrative law judge held that federal law bars a Medicare Part D plan from limiting hetlios coverage to only those non-24 patients that are blind. Following this decision, we intend to advocate with other Part D plans to strike down similar policies and improve access to Hetlios for non-24 patients, blind and sighted. Improving access and coverage of our products for patients remains a top priority, and we look forward to providing additional updates over the coming quarters. Turning to SMS for the indication of nighttime sleep disturbances. We continue to work closely with the advocacy organization, PRISMS, to engage with and support the education of the SMS community. We are looking forward to participating in PRISM's 11th International SMS Conference that begins this week. On our clinical pipeline, we are making excellent progress in advancing our late-stage programs along toward near-term milestones. Beginning with our nearest-term milestone, our Phase III clinical study of FNAF in acute manic episodes in patients with bipolar disorder is close to fully enrolled and we expect to report results by the end of 2022.
spk03: Our team has worked diligently to advance this program and we hope to deliver a new therapeutic option for patients in the near future. Moving to our traditional clinical programs, we noted last quarter that the phase three study in the prevention of motion sickness has resumed enrollment.
spk04: We are pleased with the pace of enrollment with the study now approximately 30% enrolled. As a reminder, A prior clinical study with tridipinib in motion sickness demonstrated a significantly lower incidence of vomiting in patients treated with tridipinib as compared to placebo-treated patients. On tridipinib for gastroparesis, Vanda recently held a pre-NDA meeting with the FDA to discuss the planned NDA submission for tridipinib in the short-term treatment of nausea and gastroparesis.
spk03: Following the meeting, we intend to move forward with the submission of an NDA for this indication. Vanda is continuing to conduct an open-label study of safety for tridipidin and gastroparesis.
spk04: We also continue to receive requests from patients regarding access to tridipidin through the expanded access program. We have multiple patients that have taken tridipidin for more than a year and remain on therapy, including one patient that has been on therapy for two years. Enrollment is ongoing in the clinical development programs of Hetlios for the treatment of delayed sleep phase disorder and for sleep disturbances in autism spectrum disorders.
spk03: Also of note, we are preparing for the submission of an SNDA for Hetlios in the treatment of insomnia. Additionally, I want to provide a quick update on VQW765, our alpha-7 nicotinic agonist.
spk04: I am glad to announce that our clinical study of VQW765 to alleviate social performance anxiety is fully enrolled and we expect results by the end of 2022. To conclude operational highlights, We expect 2022 to be a year in which we advance several important programs in our pipeline that we believe can contribute to Vanda's long-term growth as we continue to drive forward our commercial products.
spk03: Moving now to financial results.
spk04: I'll begin by summarizing our financial results for the first six months of 2022 before turning to discuss the second quarter of 2022. Total revenues for the first six months of 2022 were $124.6 million, a 5% decrease compared to $130.6 million for the same period in 2021. Ketlia's net product sales of $78.2 million were the primary contributor and driver of our revenues for the first six months of 2022 and saw a 7% decrease compared to $83.9 million for the same period in 2021. The first six months of 2022 reflect the continued reimbursement challenges for prescriptions of Hetlios for patients with non-24. Turning to Phenapt. Phenapt net product sales of 46.4 million for the first six months of 2022 reflect a 1% decrease compared to 46.7 million for the same period in 2021. For the first six months of 2022, Vander recorded net loss of 3.9 million compared to net income of 18.3 million for the same period in 2021. Net loss for the first six months of 2022 included an income tax provision of 100,000 as compared to an income tax provision of 4.7 million for the same period in 2021. Operating expenses for the first six months of 2022 were 128.8 million compared to 107.9 million for the first six months of 2021. The 20.9 million increase was primarily driven by both higher R&D expenses and higher SG&A expenses. The increase in R&D expenses was primarily driven by increases related to our late-stage clinical program for FNAPT, partially offset by decreases related to our tripping activities. The increase in SG&A expenses was primarily driven by higher expenses associated with legal support related to ongoing litigation, BTC awareness campaigns, sales activities, commercial support, and other corporate activities.
spk03: The end is cash.
spk04: Cash equivalents and marketable securities, referred to as cash, as of June 30, 2022, were $440.9 million, representing an increase of $44.4 million compared to June 30, 2021, and an increase of $8 million compared to December 31, 2021. Turning now to our quarterly results. Total revenues for the second quarter of 2022 were $64.4 million, a 5% decrease compared to $67.9 million for the second quarter of 2021. Hetlios net product sales were $41.2 million for the second quarter of 2022, compared to $44.5 million for the second quarter of 2021. Consistent with the first six months of 2022, net sales for the second quarter of 2022 reflect the continued reimbursement challenges for prescriptions of Hetlios for patients with non-24s. Turning to FNAPs, FNAP net product sales for the second quarter of 2022 were 23.2 million, a 1% decrease compared to 23.4 million for the second quarter of 2021. FNAP net product sales for the second quarter of 2022 were essentially flat as compared to 23.2 million for the first quarter of 2022. FNAP prescriptions for the second quarter of 2022, as reported by Equivia Exponent, were also essentially flat as compared to the first quarter of 2022. For the second quarter of 2022, Vanda recorded net income of 2.6 million compared to net income of 9.7 million for the second quarter of 2021. Net income for the second quarter of 2022 included an income tax provision of 1.2 million as compared to an income tax provision of 3 million for the same period in 2021.
spk03: Operating expenses for the second quarter of 2022 were 60.9 million compared to 55.5 million for the second quarter of 2021.
spk04: 5.4 million increase was primarily driven by higher SG&A expenses associated with sales activities, ETC awareness campaigns, and commercial support activities. Operating expenses for the second quarter of 2022 were 6.9 million lower as compared to 67.9 million for the first quarter of 2022. This decrease was primarily attributable to lower SG&A expenses associated with legal support related to ongoing litigation, commercial support activities,
spk03: ETC awareness campaigns, and other corporate activities. Vanda expects to achieve the following financial objectives in 2022.
spk04: Net product sales for both Hetlios and FNAP of between $240 and $280 million. Hetlios net product sales of between $150 and $180 million. FNAP net product sales of between $90 and $100 million. And year-end 2022 cash of greater than $440 million. This concludes our commentary regarding operational highlights and financial performance. At this point, we'll be happy to answer any questions you may have.
spk01: At this time, if you'd like to ask a question, please press star 1 on your telephone keypad. Chris Howerton with Jefferies, your line is open.
spk05: Great. Well, thanks for taking the questions, I guess. The big one I would have would be, you know, what evidence supports the strategy for hetlios and insomnia? And then as it relates to that, how would this, how would you anticipate a potential approval in insomnia impacting the pricing for hetlios? And then outside of hetlios in terms of development of tridipedin for gastroparesis, I'm curious if the discussion of the non-human toxicology studies such as the dog studies were discussed in the pre-NDA meeting and, you know, what specifically was decided with respect to a safety database and approval in that setting.
spk03: Thank you.
spk06: Thank you very much, Chris, for the questions. I will start off with the question of insomnia. And your question had to do on what evidence supports the indication. And second, if approved, what could be the pricing strategy? On the first part, as you know, tazomaltine has been approved for a chronic indication of NON24. and, of course, more recently for Smith-Mageni syndrome. We have shown that tazimelatin has a significant and large magnitude effect on improving sleep in two types of studies. One type of studies is the transient insomnia model based on phase advance. There are three studies, a smaller one and two, large studies with five-hour and eight-hour phase advance where we're showing a first-night very significant effect improving sleep parameters. And the second study is a study, a four-week duration study in patients with chronic insomnia characterized by difficulties with sleep onset. Again, there, Tezgalatin was shown to be effective both in the beginning period, this was defined as stage one and nine, as well as four weeks later in significantly improving latency to persistent sleep or sleep onset timing as compared to placebo. The combination of this evidence plus the significant experience for now almost over eight years chronically using tesmeltin for DON24, we believe supports the indication of treating chronic insomnia with sleep disturbances, likely a support for the short-term indication given that we have the four-week study data, but also an opportunity for insomnia disorder with the specification of changes in the sleep schedule, and specifically phase advance. So we will be preparing this TICANS for submission as a supplemental NDA, and we'll continue the discussions with the FDA as we prepare that filing. I will turn to your question on gastroparesis. And I believe specifically you asked on... And I will come back to pricing on Desmaltine. Specifically, you asked about the nine-month dog toxicity study and the safety database. As you know, Vander has... conducted a very large group of studies on preclinical toxicology. And therefore, the profile of the drug has been studied well in short-term and long-term studies. Long-term being a six-month rat toxicology study. And of course, two-year studies in mice. These are the carcinogenesis studies. The FDA says that the nine-month drug study is recommended through their guidance, but not required, but as we all have found out, there is no alternative they have suggested to that. Nonetheless, our many evaluations and studies to date suggest that such a study is not necessary. And we at Vander object to conduct lethal toxicology studies in animals, especially in dogs, if they are necessary. And of course, you know that there's a significant trend in public opinion to support that, especially with the recent court decision and the raid by the U.S. Department of Agriculture in a facility in Virginia where these dogs were being kept in very difficult conditions. So we believe that we have sufficient and adequate information for the FDA to conduct their review. In terms of safety, we have, again, a significant amount of data with exposures up to three months and some data with exposures of six months and a few patients over a year through the expanded access program. So we believe a combination of this information would classify as adequate to, of course, file and conduct review. But, of course, the FDA will not commit either way up until the application has been submitted and a 60-day review period on the filability of the application has been concluded. So that's where that stands. I'll go back to your question about if the insomnia study, the indication was granted, what would that mean for pricing? Of course, we all know that HETLIOS is now indicated for two orphan indications. It has a very significant price tag that we have discussed in the past that our hope was that we can identify other indications where this useful therapeutic can be used increasing the market and of course making the drug more affordable. So that's where I would stop this commentary, but then this vision is to made drugs available to patients that need them and do so and make them, make the access available again. And that means drugs that are more reasonably priced where you can do that given the much larger population of patients that can benefit. Now, what we find intriguing is that while for many years insomnia drugs, especially for sleep-onset insomnia, have been seen as sleep-promoting agents. I think there is an opportunity with the circadian regulator like tazimeltin to actually establish a new thinking that it may be that a large number of patients with pure sleep-onset insomnia may actually have a change in their sleep schedule, which is because of a circadian challenge. So this may be a circadian etiology within sleep-conscious insomnia, and this is perhaps why this drug has worked and worked very well in the four-week insomnia study. I know long answers, but please let me know if you have any follow-up.
spk05: Yeah, no, very, very much appreciated my house. I do. I do have a follow up. And with respect to the plan for submission for insomnia, could you give us maybe a an overview of what a timeline might be expected and have you or do you plan to meet with the FDA regarding the submission before you actually do so?
spk06: We have already met with the FDA and we will continue the discussions. As I said, there are potentially two indications. One being the short-term treatment of insomnia, chronic insomnia, characterized by disturbances of sleep onset. And the second one, what is in the DSM-5, other insomnia disorder characterized by change in sleep schedule. So these discussions will continue. This is a different mechanism of action than the FDA has approached, but I remind everyone that the indication I mentioned first, short-term treatment of insomnia characterized by sleep-oxygen disturbances, is exactly what the indication reads for Ambien. So there's nothing new there, and... you know, we do expect there will be some significant discussions with the FDA as we proceed. In terms of timing, of course, this is supplemental NDA. And unlike NDA said, require putting together the entire package, you know, preclinical safety manufacturing, all this information is there. And therefore, we believe it's a bit more straightforward and therefore, It will take less amount of time to prepare. I cannot commit right now to timing as we want to continue these discussions with the agency.
spk05: Okay. No, that's fantastic. And I guess if I may just ask one more question. I don't know if it would be directed to you, Mahalas, or Kevin. But with respect to some of the changes that you have observed in terms of Medicare Part D coverage, did that impact your financial guidance? Or, like, how did that weigh into your thinking for the revenues for this year?
spk06: Yeah, I'll start off by briefly saying that this is an emerging story. And, you know, the... highlight that Kevin gave for that single cited patient who actually won the administrative law judge hearing is exemplary that there is energy both by the patients but also adjudicators to do the right thing. Stick to the FDA label and improve access for patients. But it is all at the beginning And you remember that starting back in December and more this year, we had actually several successes with state Medicaid agencies actually revising the criteria to allow access to sighted patients. But I will let Kevin discuss the impact.
spk04: Yep. Thanks, Miles. And Chris, just as a reminder for our guidance on hetliosia, it was 150 to 180 million, and what we had spoken to on that was the lower end of the range assumed that we continued to see payer challenges that resulted in a decline in patients on therapy, and the upper end of the range reflected, you know, improvement in those dynamics and, you know, return to growth on patients on therapy. You know, obviously we've affirmed guidance as of our Q2 release. and, you know, appear to be kind of trending towards somewhere in the middle of those two stories. And as Mahalis mentioned, you know, this is recent news that we're continuing to evaluate, and we'll see, you know, what the impact will be as we go forward and look to have that guidance, you know, taken into account by other Medicare plans, you know, for patient-seeking treatment. So, you know, breaking, you know, kind of news on that that we'll have to continue to monitor and evaluate. Okay.
spk05: Yeah, okay. No, that's very helpful. Thank you, Kevin. Okay, well, I think those are all my questions for the time being. I really appreciate you taking them.
spk06: Thank you very much, Chris.
spk02: There are no further questions at this time. I would like to turn the call back over to Vanda Management for closing remarks.
spk06: Thank you. Thank you very much for joining us today. We look forward to speaking with you again soon.
spk01: This concludes the Q2 2022 Vanda Pharmaceutical, Inc. earnings call. We thank you for your participation. You may now disconnect.
Disclaimer